Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4219113 | 0.92 | LPL (0.38) | LPLLIPGTRPV4ESR2ROCK1 | |
| SCHEMBL16534950 | 0.89 | LPL (0.38) | LPLLIPGTRPV4ESR2ROCK1 | |
| SCHEMBL25399101 | 0.89 | LPL (0.38) | LPLLIPGTRPV4ESR2ROCK1 | |
| SCHEMBL27198578 | 0.86 | LPL (0.36) | LPLLIPGTRPV4ESR2ROCK1 | |
| SCHEMBL20253387 | 0.86 | LPL (0.36) | LPLLIPGTRPV4ESR2ROCK1 | |
| SCHEMBL30827381 | 0.86 | LPL (0.36) | LPLLIPGTRPV4ESR2ROCK1 | |
| SCHEMBL24492663 | 0.83 | LPL (0.32) | LPLLIPGTRPV4 | |
| SCHEMBL22802575 | 0.82 | ESR2 (0.41) | LPLLIPGESR2CA1CA2 | |
| SCHEMBL18339421 | 0.81 | LPL (0.40) | LPLLIPGTRPV4ESR2ROCK1 | |
| SCHEMBL17667860 | 0.80 | ESR2 (0.39) | LPLLIPGESR2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250359476-A1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | KYULUX INC (JP) | 2025-11-20 | — | — | US | disclosed |
| US-12369492-B2 | Composition of matter for use in organic light-emitting diodes | KYULUX, INC. (JP) | 2025-07-22 | — | — | US | disclosed |
| EP-4498784-A2 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | Kyulux, Inc. (JP) | 2025-01-29 | — | — | EP | disclosed |
| EP-3775100-B1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | KYULUX INC (JP) | 2025-01-22 | — | — | EP | disclosed |
| US-11825743-B2 | Organic molecules for use in organic optoelectronic devices | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-21 | — | — | US | disclosed |
| US-11825743-B2 | Organic molecules for use in organic optoelectronic devices | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-21 | — | — | US | disclosed |
| EP-3585777-B1 | ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | SAMSUNG DISPLAY CO LTD (KR) | 2023-05-10 | — | — | EP | disclosed |
| CN-115960074-A | Fluorine-containing ferroelectric liquid crystal molecules containing heteroatom hexatomic alicyclic ring and synthesis method thereof | 华南理工大学 | 2023-04-14 | — | — | CN | disclosed |
| EP-3645522-B1 | ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2021-10-13 | — | — | EP | disclosed |
| US-20210135119-A1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | KYULUX, INC. (JP) | 2021-05-06 | — | — | US | disclosed |
| WO-2010059658-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-05-27 | — | — | WO | disclosed |
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090131457-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2026811-A1 | PYRAZOLO [3, 4-D]PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | Novartis AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| WO-2007134828-A1 | PYRAZOLO [3, 4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| EP-1776357-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | Astellas Pharma Inc. (JP) | 2007-04-25 | — | — | EP | disclosed |
| US-20060052599-A1 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2006-03-09 | — | — | US | disclosed |
| WO-2006016680-A1 | HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) | ASTELLAS PHARMA INC. (JP) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11825743-B2 | Organic molecules for use in organic optoelectronic devices | OR10J3, OR51E2, OCIAD2 | LPL 4441/4885LIPG 2090/4885TRPV4 243/4885 |
| US-20060052599-A1 | HDAC inhibitor | HDAC1, HDAC2, HDAC11 | LPL 1759/4885LIPG 4315/4885TRPV4 3633/4885 |
| US-20090131457-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | PIK3CA, JAK3, PDK1 | LPL 4216/4885LIPG 3781/4885TRPV4 1630/4885 |
| US-20210135119-A1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | CRY2, SLCO1B3, NDUFV3 | LPL 845/4885LIPG 1415/4885TRPV4 227/4885 |
| US-20250359476-A1 | COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES | CRY2, SLCO1B3, NDUFV3 | LPL 845/4885LIPG 1415/4885TRPV4 227/4885 |
| US-20090054464-A1 | HDAC INHIBITOR | HDAC1, HDAC2, HDAC8 | LPL 1367/4885LIPG 4465/4885TRPV4 3880/4885 |
| US-12369492-B2 | Composition of matter for use in organic light-emitting diodes | CRY2, SLCO1B3, NDUFV3 | LPL 845/4885LIPG 1415/4885TRPV4 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.